Atai Life Sciences NV

Atai Beckley N.V. filed a prospectus supplement to register common shares related to its acquisition of Beckley Psytech Limited, fulfilling contractual rights.

AtaiBeckley announced Q3 2025 financial results, highlighted by FDA Breakthrough Therapy designation for BPL-003 and a strengthened balance sheet extending operations into 2029.

Atai Beckley N.V. filed a prospectus supplement to register 5.3 million common shares for resale by existing securityholders, fulfilling prior acquisition-related registration rights.

Atai Life Sciences and Beckley Psytech successfully completed their strategic combination, forming AtaiBeckley, a clinical-stage biopharmaceutical company focused on mental health treatments.

ATAI Life Sciences shareholders approved the acquisition of Beckley Psytech, a redomiciliation to Delaware, and key director appointments at an extraordinary general meeting.

ATAI Life Sciences N.V. has amended its Share Purchase Agreement with Beckley Psytech Limited, reducing the number of shares issued to Beckley Psytech shareholders and allocating shares to Cantor Fitzgerald & Co. for advisory services.

Atai Beckley N.V. reported increased net losses for Q3 2025, driven by higher operating expenses, but secured significant capital and advanced its psychedelic-based neuroplastogen pipeline, including a Breakthrough Therapy designation for BPL-003.

ATAI Life Sciences N.V. reported a significantly reduced net loss for the first half of 2025, bolstered by successful capital raises and positive clinical data for BPL-003, despite a delay in its VLS-01 program.

ATAI Life Sciences reports its financial results for the first quarter of 2025, providing updates on its clinical-stage pipeline and strategic initiatives.

ATAI Life Sciences N.V. has filed an amendment to its quarterly report to correct signature omissions in certifications, with no changes to the financial data.

ATAI Life Sciences reported a net loss of $110.3 million for the first nine months of 2024, alongside updates on its clinical pipeline and strategic initiatives.

ATAI Life Sciences reported its Q2 2024 financial results, highlighting a net loss but also progress in its clinical programs and strategic capital allocation.

ATAI Life Sciences' 2024 10-K filing reveals a year of strategic shifts, clinical advancements, and financial recalibration in the pursuit of mental health treatments.

ATAI Life Sciences N.V.'s 10-K filing provides a comprehensive overview of its share capital, articles of association, and corporate governance practices, highlighting its commitment to developing treatments for mental health disorders.

Atai Life Sciences Chief Medical Officer, Craig Kevin James, executed a Rule 10b5-1 trading plan, involving option exercises and stock sales.

Gerd Kochendoerfer, Chief Operating Officer of Atai Life Sciences, reported transactions involving the sale of 50,000 common shares and the exercise of stock options.

Atai Beckley N.V. director Cosmo Feilding-Mellen's stock option award was amended, reducing shares to 10,000 but accelerating vesting to December 31, 2025.

Atai Beckley N.V. director Robert Hershberg was granted stock options following the acquisition of Beckley Psytech Limited.

Atai Beckley N.V. Director Cosmo Feilding-Mellen reported significant share and option acquisitions following the completion of the Beckley Psytech acquisition.

Atai Beckley N.V. Director Scott Braunstein was granted 56,818 stock options with an exercise price of $5.28, vesting fully on November 4, 2026.

ATAI Life Sciences and Beckley Psytech announced that the U.S. FDA granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression, signaling potential for expedited development.

ATAI Life Sciences is moving forward with its acquisition of Beckley Psytech, which reported increased losses but positive Phase 2b results for BPL-003 and secured $10M funding.

ATAI Life Sciences N.V. announced its definitive agreement to acquire Beckley Psytech Limited, following positive Phase 2b clinical trial results for BPL-003 and a $50 million PIPE financing.

ATAI Life Sciences N.V. proposes to acquire Beckley Psytech Limited and redomicile to Delaware, aiming to enhance its psychedelic-based mental health pipeline and streamline corporate structure.

ATAI Life Sciences and Beckley Psytech announced positive Phase 2a clinical trial results for BPL-003, showing improved and sustained antidepressant effects with a two-dose regimen in treatment-resistant depression patients.

ATAI Life Sciences announced positive Phase 2b results for BPL-003 in TRD, a planned strategic combination with Beckley Psytech, and extended cash runway into H2 2027.

ATAI Life Sciences N.V. reported a reduction in its beneficial ownership of COMPASS Pathways plc to 6.0% through recent open market sales.

Apeiron Investment Group and related entities increased their beneficial ownership in ATAI Life Sciences N.V. to 24.0% following a share conversion and a new lock-up agreement.

Apeiron Investment Group and affiliates increased their beneficial ownership in ATAI Life Sciences N.V. to 24.3% through a $19 million PIPE financing.

Apeiron Investment Group and its affiliates have increased their beneficial ownership in ATAI Life Sciences N.V. to 22.2%, securing significant voting rights, board representation, and registration rights through new agreements.

ATAI Life Sciences N.V. and its subsidiary ATAI Life Sciences AG have filed an Amendment No. 4 to Schedule 13D, disclosing a beneficial ownership of 7.5% in COMPASS Pathways plc as of March 5, 2025.

Apeiron Investment Group and its controlling shareholder Christian Angermayer have significantly increased their beneficial ownership in ATAI Life Sciences N.V. to 22.7% following the company's recent $55 million registered offering.

Galaxy Group Funding ECI U LLC, Galaxy Group Investments LLC, and Michael E. Novogratz have collectively reduced their beneficial ownership in ATAI Life Sciences N.V. to 4.2% of common shares.